|Articles|August 21, 2007

Silence Therapeutics Appoints New CEO

Author(s)BioPharm International Editors

Silence Therapeutics (London, England, www.silence-therapeutics.com) has appointed Jeffrey Scott Vick as Group CEO.

Silence Therapeutics (London, England, www.silence-therapeutics.com) has appointed Jeffrey Scott Vick as Group CEO. With this appointment, the company hopes to strengthen its core management team and expand its business partnerships. Vick has held senior positions in the healthcare industry in both Europe and the US, gaining experience as a business analyst and biotech venture capitalist. He has worked in the drug development sector for five years in senior management roles with DepoTech Corporation.

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

AbbVie and Genmab say epcoritamab plus R-CHOP improved progression-free survival in newly diagnosed DLBCL; regulator talks are planned. Credit: Stock.Adobe.com/David A Litman.

October 6th, 2026

Epcoritamab Plus R-CHOP Improves Progression-Free Survival in Newly Diagnosed DLBCL in Phase 3 EPCORE DLBCL-2 Trial

Topline phase 3 data show epcoritamab plus R-CHOP reduced the risk of progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma.

After Part 1 maintenance data, Viking is testing oral tablets and less frequent injections to sustain weight loss from 21 weeks of weekly VK2735 dosing. Credit: Stock.Adobe.com/Daniel Krasoń

October 6th, 2026

Viking Begins Oral VK2735 Maintenance Trial in Obesity After Subcutaneous Dosing Data

Part 2 of the VK2735 maintenance study tests whether daily or weekly oral tablets can hold weight loss first achieved with weekly subcutaneous injections.

Human Body Organs Anatomy (Liver with Kidneys): Image credit: © magicmine - © magicmine - stock.adobe.com

October 6th, 2026

CSL, Alentis Partner on Claudin-1 MAb Lixudebart for Kidney Disease

CSL and Alentis will co-develop lixudebart, an antibody targeting claudin-1, across 3 rare kidney and liver disease indications.

The X-ray of the human brain | Image credit: © merydolla - © merydolla - stock.adobe.com

October 6th, 2026

Alector, Genentech Ink Deal for Parkinson Therapy AL050

AL050 aims to treat GBA1-driven Parkinson disease by delivering a GCase enzyme across the blood-brain barrier.

October 5th, 2026

The BioPharm Brief: Obesity Data and Manufacturing Shape Drug Progress

Survodutide advances metabolic disease treatment, while biosimilar capacity expands, FDA delays hemophilia review, and lupus data support next steps.

In 52-week phase 2 AMETHYST data, 27.2% of participants with cutaneous lupus reached clear or almost clear skin on litifilimab, up from 19.0% at week 24. (153 characters). Credit: Stock.Adobe.com/Love Employee

October 5th, 2026

Litifilimab Shows Sustained Skin Responses at 52 Weeks in Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus

Litifilimab extended skin responses through 52 weeks in phase 2 AMETHYST data in cutaneous lupus erythematosus, with phase 3 results expected in 2027.

FDA drug approval process, pharmaceutical regulatory compliance, food and drug administration certification, medical product approval concept, drug testing and approval | image credit: © Сергей Шиманович - © Сергей Шиманович - stock.adobe.com

October 5th, 2026

FDA Delays Novo Nordisk's Denecimig Over Facility Fixes

Manufacturing remediation, not efficacy or safety data, is delaying US approval of Novo's h+emophilia A therapy denecimig.

Group of Vaccine bottles. Medicine in ampoules. Glass vials for liquid samples in laboratory. | Image credit: © ronnarong - © ronnarong - stock.adobe.com

October 5th, 2026

Alvotech Wins FDA Nod for 2nd Simlandi Manufacturing Suite

Doubled drug substance capacity at Alvotech's Reykjavik, Iceland, site aims to secure steady US supply of the Humira biosimilar Simlandi.